These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21358201)

  • 1. Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.
    Karabay CY; Kocabay G; Kalayci A; Zehir R; Tanboga H
    Cardiology; 2010; 117(4):296-300. PubMed ID: 21358201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does Trastuzumab cause permanent severe mitral regurgitation?
    Günaydın ZY; Bektaş O; Çiltaş A; Karagöz A; Kaya A
    Int J Cardiol; 2015 Mar; 182():8-9. PubMed ID: 25576708
    [No Abstract]   [Full Text] [Related]  

  • 3. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study.
    Ho E; Brown A; Barrett P; Morgan RB; King G; Kennedy MJ; Murphy RT
    Heart; 2010 May; 96(9):701-7. PubMed ID: 20424152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
    Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
    Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardiac safety of trastuzumab in the treatment of breast cancer.
    Chien AJ; Rugo HS
    Expert Opin Drug Saf; 2010 Mar; 9(2):335-46. PubMed ID: 20175700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab.
    Hare JL; Brown JK; Leano R; Jenkins C; Woodward N; Marwick TH
    Am Heart J; 2009 Aug; 158(2):294-301. PubMed ID: 19619708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional mitral regurgitation and papillary muscle dyssynchrony in patients with left ventricular systolic dysfunction.
    Güler A; Dündar C; Tigen K
    Anadolu Kardiyol Derg; 2011 Aug; 11(5):450-5. PubMed ID: 21733790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of papillary muscle dyssynchrony in predicting the severity of functional mitral regurgitation in patients with non-ischaemic dilated cardiomyopathy: a two-dimensional speckle-tracking echocardiography study.
    Tigen K; Karaahmet T; Dundar C; Guler A; Cevik C; Basaran O; Kirma C; Basaran Y
    Eur J Echocardiogr; 2010 Sep; 11(8):671-6. PubMed ID: 20237053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute effects of initiation and withdrawal of cardiac resynchronization therapy on papillary muscle dyssynchrony and mitral regurgitation.
    Ypenburg C; Lancellotti P; Tops LF; Bleeker GB; Holman ER; Piérard LA; Schalij MJ; Bax JJ
    J Am Coll Cardiol; 2007 Nov; 50(21):2071-7. PubMed ID: 18021876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of cardiac dysfunction after herceptin treatment in patients with metastatic breast cancer by echocardiography].
    Hattori K; Nishi Y; Nakamura S; Misao H; Kikuchi M; Sasaki R; Takeda K
    Rinsho Byori; 2007 Feb; 55(2):120-5. PubMed ID: 17390714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads.
    Sengupta PP; Northfelt DW; Gentile F; Zamorano JL; Khandheria BK
    Mayo Clin Proc; 2008 Feb; 83(2):197-203. PubMed ID: 18241629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab-associated cardiotoxicity.
    Keefe DL
    Cancer; 2002 Oct; 95(7):1592-600. PubMed ID: 12237930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant trastuzumab in breast cancer: experience from the University of Florence.
    Livi L; Borghesi S; Meattini I; Saieva C; De Luca Cardillo C; Scotti V; Mangoni M; Galardi A; Cataliotti L; Paiar F; Bianchi S; Biti G
    J Chemother; 2010 Apr; 22(2):115-8. PubMed ID: 20435571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
    Garnock-Jones KP; Keating GM; Scott LJ
    BioDrugs; 2010 Jun; 24(3):207-9. PubMed ID: 20462285
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Trastuzumab-associated cardiac dysfunction].
    Okada Y; Kanbayashi C; Sato N
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):665-9. PubMed ID: 20414023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A throbbing pain in the head: trastuzumab-induced migraine.
    van Rooij FG; Dorresteijn LD; Van Bokhoven MM; Verstappen CC
    Anticancer Res; 2009 Oct; 29(10):4223-5. PubMed ID: 19846977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Left Ventricular Torsion in Papillary Muscle Relocation for Severe Functional Mitral Regurgitation].
    Yoshida K; Hayashi C; Nakai H; Hyoudou E; Tamita K; Yamamuro A; Yoshikawa J
    Kyobu Geka; 2015 Dec; 68(13):1045-8. PubMed ID: 26759942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when.
    Olver IN
    Future Oncol; 2008 Feb; 4(1):125-31. PubMed ID: 18241007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accessory mitral papillary muscle causing severe aortic insufficiency.
    Ucak A; Onan B; Alp I; Yılmaz AT
    Turk Kardiyol Dern Ars; 2010 Dec; 38(8):564-7. PubMed ID: 21248456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.